17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
5 citations
,
January 2021 in “Journal of Cosmetic Dermatology” Topical cetirizine 1% promotes hair growth in male androgenetic alopecia patients.
65 citations
,
October 2008 in “Journal of Neuroendocrinology” 1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
October 1995 in “Pediatric Research” January 2007 in “Journal of Clinical Dermatology” The topical solution increased hair count but wasn't significantly better than placebo in other measures.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
4 citations
,
January 1991 in “Journal of obstetrics and gynaecology” The photographic method accurately measures hair growth and both treatments effectively reduced hair growth in hirsute women.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
24 citations
,
July 1983 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by blocking male sex hormones.
A 10-year-old girl's symptoms improved after surgery to remove a benign adrenal tumor.
4 citations
,
November 2018 in “Endocrinology, Diabetes & Metabolism Case Reports” GnRH analogue can help diagnose ovarian causes of high testosterone in postmenopausal women when scans don't show the cause.
2 citations
,
April 2022 in “Annales d Endocrinologie” Recombinant gonadotropins improve future fertility in CHH patients.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
January 2026 in “International Journal of Women s Health” A new model helps predict treatment success in girls with early puberty.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
June 1995 in “International Journal of Gynecology & Obstetrics” Cabergoline is more effective and has fewer side effects than bromocriptine for treating women with hyperprolactinemic amenorrhea.